ERBB2 and breast cancer: However, therapy with the monoclonal, humanized anti-HER2 antibody trastuzumab and other anti-HER2 therapeutic agents considerably improved outcome of HER2+ BC in the past two decades, although about 50% of patients still experience de novo or acquired resistance [2].